Neurocrine Biosciences (NBIX) EPS (Basic) Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) EPS (Basic) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 50.53% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 6.20% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -70.04% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 6.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -6.51% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 65.05% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -18.26% |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 31.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65.05% |
| Dec 31, 2025 | 18.47% |
| Sep 30, 2025 | 43.38% |
| Jun 30, 2025 | 101.18% |
| Mar 31, 2025 | -18.40% |
| Dec 31, 2024 | 148.29% |
| Sep 30, 2024 | 75.48% |
| Jun 30, 2024 | 12.98% |
| Mar 31, 2024 | 8.47% |
| Dec 31, 2023 | -26.04% |
| Sep 30, 2023 | 50.00% |
| Jun 30, 2023 | 4.56% |
| Mar 31, 2023 | -58.12% |
| Dec 31, 2022 | 35.77% |
| Sep 30, 2022 | 6.89% |
| Jun 30, 2022 | -32.29% |
| Mar 31, 2022 | 28.67% |
| Dec 31, 2021 | -33.34% |
| Sep 30, 2021 | -24.88% |
| Jun 30, 2021 | 26.14% |